DOCSLIB.ORG

3Rd FCF Life Science Venture Capital Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
3Rd FCF Life Science Venture Capital Report FCF Life Science Research 3rd Life Science Venture Capital Report – Financing Trends in Europe and the US Fungi Penicillium Part of FCF Life Science Research Series Executive Summary FCF Overview Funding Development in 2018 Life Sciences: A closer Look C r o s s - border Investment Activity Investor Analysis Life Science Exits 2 Executive Summary The FCF Life Science Venture Capital FCF Life Science Venture Capital Report Recipients Report is a is a comprehensive, standardized analysis for biotechnology, The FCF Life Science Venture Capital Report targets the following standardized report pharmaceutical and medical technology companies, examining recipients: focusing on venture recent venture capital deal trends in the European life science ▪ Corporates / Executives ▪ Venture capital investors capital deal industry ▪ Institutional investors ▪ Family Offices / High- characteristics in the ▪ Private equity investors net-worth individuals biotechnology, ▪ Advisors Selection of Companies pharmaceutical and medical technology The selection of companies is based on the following criteria: Availability segments, and can be used as a quick ▪ Companies operating in the biotechnology, pharmaceutical, The FCF Life Science Venture Capital Report is available on FCF’s reference for medical technology, services or other life science related sectors website at “https://www.fcf.de/de/research/life-science-research“ investors, corporates ▪ Sole focus on transactions involving European life science and professionals companies Data ▪ The therapeutics sector is further divided into the following All input data is provided by Pitchbook, S&P Capital IQ or More advanced, indications: Oncology, Central Nervous System, Infectious GlobalData and is not independently verified by FCF. Ratio and detailed and / or Diseases, Immunology, Ophthalmology, Rare Diseases, multiple calculations are driven based on the input data available. Respiratory, Diversified and Others. customized reports For additional information and disclaimer, please refer to the last page are available upon request To recommend colleagues or fellow investors to be added to the If you have questions, comments or ideas, please do not hesitate mailing list, kindly send an email with the respective contact to contact us information 3 Executive Summary FCF Overview Funding Development in 2018 Life Sciences: A closer Look C r o s s - border Investment Activity Investor Analysis Life Science Exits 4 FCF Overview FCF seeks to provide Who We Are Capital Markets Capabilities and Services its clients with ▪ Specialized investment bank and financing specialist financing solutions Private / ▪ Venture capital ▪ Private equity ▪ Advising public and private small / midcap companies Pre-IPO ▪ Growth capital (i) at the lowest cost, ▪ Advisor for structuring and placement of financing transactions: ▪ Initial Public Offering (IPO) pursued in tandem) – All instruments: Unbiased approach to all available corporate Equity / Capital increase ▪ Private Investment in Public (ii) with the highest Public ▪ Dual-track (IPO and Equity (PIPE) flexibility, financing instruments (no product selling approach), allowing alternative transaction ▪ Block trade for customized financing structures (iii) in the shortest ▪ Receivables / Factoring / ▪ Working capital / Revolving – All investors: Close and trusted relationships with senior period of time, Short-term ABS credit facility executives of virtually all relevant equity and debt investors Debt ▪ Borrowing base / ▪ Guarantees / (iv) with the highest – Fast process: Process management skills and direct / personal Inventory Letter of Credit closing proba- access to institutional debt and equity investors enable fast ▪ Bank loan facility / ▪ Promissory note Syndicated loans (Schuldscheindarlehen) bility, and with transactions Debt Long-term ▪ Sale-and-lease back / ▪ High-yield / PIK bond (v) financing partners Debt Leasing ▪ Second lien / Subordinated ▪ More than 100 transactions with a total placement volume in ▪ Corporate bonds (public / loans that integrate well excess of EUR 4.0 billion since foundation in 2005 private placement) ▪ Unitranches into their strategy ▪ Approx. 10 professionals headquartered in Munich Mezzanine ▪ Mezzanine capital ▪ Convertible bonds Selected Transactions Acquisition Financing Senior Loan & WCF GSE Group Acquisition by Finexx [confidential] December 2018 5 FCF in the Life Science Sector Life Science Overview Advisory Services Life Science Team Focus on Midcap and R&D Companies ✓ ✓ Integrated Management Financial Presentation FCF has traditionally served Small- and Midcap companies in the German speaking Modeling region, providing customized and innovative financing solutions, with mandates in the Pharmaceuticals sector. Arno Dr. Mathias Sebastian Colin FCF has expanded its focus on the Life Science sector, closing 4 Life Science ✓ ✓ Fuchs Schott Sommer Saß Post- CEO Director Analyst Analyst transactions in 2017: Investor Transaction Screening Support ✓ ✓ Due Diligence Investor / IB Dr. Alexandra Prof. Dr. Horst Claus Dr. Holger Support Roadshow Goll Domdey Schalper Bengs Former General Co-Founder of Co-Founder & former Founder & CEO Partner Medigene AG and CFO Pieris Pharma BCNP Consultants TVM Capital board member of ✓ ✓ BioM AG Pipeline Financing Advisory Financing Click picture to Equity & Debt FCF Life Science Research Series view the report Strategy FCF is currently advising companies FCF advises with its dedicated Life Fundraising Advisory in following indications regarding Science team on the following The FCF Life Science VC Report analyses equity and debt transactions: transaction types: the latest Venture Capital funding activities in ✓ ✓ the Life Science sector in Europe and the US. Venture Term Sheet Closing Negotiation Assistance Capital The FCF Life Science IPO Report examines recent IPO trends in the Life Science sector, Oncology Central Nervous Infectious with a strong focus on the comparison of System Diseases ✓ ✓ European and US characteristics. Life Science IPO IPO Venture Advisory Execution The FCF Life Science Monitor is the most Advisory Debt Board Support detailed analysis of European publicly listed Respiratory MedTech HealthTech companies, from the Life Science sectors. (extract from service portfolio) 6 FCF Facts & Figures More than Close to More than More than # 1 10 100 100 4 bn Financing Advisor in Investment Banking Years of aggregated, Completed Total volume of Germany, purely Professionals investment banking / Transactions advised & closed focusing on corporate financing experience transactions since financing transactions 2005 More than More than Network 2000 25 120 Leading Access to more than Contacts to Family International Articles and research Advisor for Financing 4000 international Offices and Ultra High conferences organized papers published Transactions with financial institutions Net Worth Individuals EIB in the DACH worldwide region 7 Executive Summary FCF Overview Funding Development in 2018 Life Sciences: A closer Look C r o s s - border Investment Activity Investor Analysis Life Science Exits 8 European Life Science Venture Capital Volumes over Time Financing volumes EURm # of Deals per year have been 250 steadily increasing EUR 3,011m 3,000 since 2000, reaching a new record high of approximately EUR 213 200 3bn in 2018. 2,500 Funding volumes of the last seven years 2,000 are above the 150 average annual deal volume of Average Annual Deal Volume (2000-2018): EUR 1,150m 1,500 EUR 1,150m (2000 – 2018) 100 The number of transactions per year 1,000 is also increasing steadily 50 500 0 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 European Deal Volume European Deal Count Source: PitchBook as of 31.12.2018, FCF Equity Research 9 Most Active European Life Science Countries in 2018 In 2018, the Life Top 5 Active Countries – by Deal Volume Top 5 Active Countries - by Deal Volume Science industry in EURm the UK recorded the highest deal volume 95 United Kingdom United Kingdom 1,226 with EUR 1,225m, 8% Deals followed by Germany 11% Germany Germany 10 357 and France with deal Deals volumes of EUR EURm 14% 52% France 17 2,339 France 319 357m and EUR 319m Deals respectively Belgium 15 Belgium 247 15% Deals Ireland The UK’s deal activity 8 Ireland 191 more than doubles Deals that of the other countries in the top 5 by deal volume Top 5 Active Countries – by Number of Deals Top 5 Active Countries – by Average Deal Volume combined EURm 3 Denmark 40.3 Deals Danish Life Science 8% United Kingdom companies received 10% Germany 10 35.7 the highest average Switzerland Deals 11% deal volumes of EUR 157 8 France Ireland 23.9 40.3m, while only Deals Deals recording 3 deals and 60% 11% 17 Belgium France 18.7 is followed by Deals Germany with an Netherlands 15 Belgium 16.4 average deal volume Deals of EUR35.7m and a deal count of 10 Source: PitchBook as of 31.12.2018, FCF Equity Research 10 Top 10 European Life Science Deals in 2018 by Volume The 2nd round of BioNTech SE EUR 222m Artios Pharma Ltd. EUR 73m 2nd round / 2018 3rd round / 2018 BioNTech with EUR Fidelity Management & Research, Invus Group, Janus AbbVie Ventures, Andera Partners, Arix Bioscience, IP Group, Life 222m is leading the 1. Henderson Group, Redmile Group, The Struengmann 6. Sciences Partners, Merck Ventures, Novartis Venture Fund, Pfizer Family Office (5) Ventures, SV Health Investors (9) league table of the Indication: Oncology Indication: Oncology largest Life Science VC rounds in Europe in 2018
Load more

Recommended publications
  • CYAD JP Morgan Itinerary
    Corporate Access Event January 11 - 14, 2016 Meeting Schedule, January 11th – 14th San Francisco, CA French Biotech Co. CEO, CFO VP Business Development Strategic Advisor Immuno-Oncology Company Meeting Location: Sir Francis Drake Hotel Room # 450 P owell Street San Franc isco, CA If questions should arise, please contact: Andrew McDonald Mobile: Email: [email protected] Angela Qian Mobile: Email: [email protected] -1 Corporate Access Event January 11 - 14, 2016 MEETINGS Note: (*) indicates that this meeting time is double-booked. Meeting Time Room Meeting With Note Type Monday, January 11, 2016 08:00-09:00 am Sir Francis Drake (450 1x1 Aquilo Capital Powell St), Room 530 Patrick Rivers 09:00-10:00 am Sir Francis Drake (450 1x1 Auriga Capital Powell St), Room 530 Glen Losev 10:00-11:00 am Hotel Nikko (222 Mason 1x1 Takeda St), 25th Floor, Bay Kiran Philip View Room 11:00-12:00 pm Sir Francis Drake (450 1x1 Granite Investment Partners LAST MINUTE Powell St), Room 530 Jeffrey Hoo CANCELLATION 12:00-1:00 pm Marriott Marquis (780 1x1 AbbVie Onsite Contact: Mission St), Salon 14 Niels Emmerich Tiffany Cincotta-Janzen, (847) 393-5723 01:30-02:00 pm Sir Francis Drake (450 1x1 Alpine BioVentures, GP LLC Powell St), Room 530 David Miller 03:00-03:30 pm Sir Francis Drake (450 1x1 Tara Capital Grp Powell St), Room 530 Dhesh Govender 04:00-05:00 pm Sir Francis Drake (450 1x1 EVOLUTION Life Science Partners Powell St), Room 530 Anton Gueth Tuesday, January 12, 2016 07:00-08:30 am* Breakfast Fierce Biotech Big Data Breakfast CEO will attend.
    [Show full text]
  • 80 Investors: Longevity in Switzerland 3Wventures
    80 Investors: Longevity in Switzerland 3wVentures 3wVentures provides seed money and venture capital to international internet startups. As 3wVentures' clients focus on early stage projects and prototypes, the company's investments and co-investments target a volume of up to USD 250,000. 3wVentures is located in Switzerland and backed by Yves Latour and Arvin Zuberbuehler. 3wVentures has invested early stage venture capital in these startup companies: forAtable.com, Lunchgate, UEPAA! etc. Web site: 3wventures.com Number of Investments: 44 Total Investments: $23.3M Founded in: 2007 Based in: Herisau, Switzerland Sector: P3, AgeTech Investment in Switzerland companies: Pregnolia, Abionic Stages: Early Stage Venture, Seed 231 Aescap Venture Aescap 2.0 is an open-end fund that invests in publicly listed biotech / life sciences companies. It invests in highly innovative companies that develop and market new medicines and to a lesser extent diagnostics and/or medical devices. Entry into and exit from the fund is possible twice per month. The life sciences market is a large and fast-growing market where breakthrough innovations can be harnessed in a global and profitable manner. Aescap 2.0 has a focused portfolio, investing in approximately 18 companies. Within this focus it will ensure that the portfolio is diversified over different diseases and company development phases. The Fund’s objective is to make an annual net return (after deduction of costs) of 20% over the mid-term (4-5 years). Web site: aescap.com Number of Investments: 26 Total Investments: $30.5M Founded in: 2005 Based in: Amsterdam, The Netherlands Sector: Regenerative Medicine Investment in Switzerland companies: Vivendy Therapeutics Stages: Early Stage Venture, Late Stage Venture 2 Angel Investment Network Angel Investment Network is a London-based investment company founded in 2004 whose aim is to connect entrepreneurs and investors.
    [Show full text]
  • RRP Sector Assessment
    OrbiMed Asia Partners III, LP Fund (RRP REG 51072) OWNERSHIP, MANAGEMENT, AND GOVERNANCE A. The Fund Structure 1. The Asian Development Bank (ADB) proposes to invest in OrbiMed Asia Partners III, LP Fund (OAP III), which is a Cayman Islands exempted limited partnership seeking to raise up to $500 million in capital commitments. It is managed by OrbiMed Asia GP III, LP (the general partner), a Cayman Islands exempted limited partnership. The sole limited partner of the general partner is OrbiMed Advisors III Limited, a Cayman Islands exempted company. OrbiMed Advisors LLC (the investment advisor), a registered investment advisor with the United States (US) Securities and Exchange Commission, will provide investment advisory services to OAP III. This structure is illustrated in the figure below. Table 1 shows the ultimate beneficial owners (UBOs) of the general partner and the investment advisor. Table 1: Ultimate Beneficial Owners of the General Partner and the Investment Advisor (ownership stake, %) Name Investment Advisor General Partner Sven H. Borho (~10–25%) (~8%) Alexander M. Cooper (~8%) Carl L. Gordon (~10–25%) (~8%) (also Director) Geoffrey C. Hsu (<5%) (~8%) Samuel D. Isaly (~50–75%) (~8%) W. Carter Neild (<5%) (~8%) (also Director) Jonathan T. Silverstein (~5–10%) (~8%) (also Director) Sunny Sharma (~8%) (also Officer) Evan D. Sotiriou (~8%) David G. Wang (~8%) (also Officer) Jonathan Wang (~8%) (also Officer) Sam Block III (~8%) Source: OrbiMed Group. 2 2. Investors. The fund held a first closing of approximately $233.5 million on 1 March 2017, and a second closing of approximately $137.6 million on 26 April 2017.
    [Show full text]
  • Corporate Venturing Report 2019
    Corporate Venturing 2019 Report SUMMIT@RSM All Rights Reserved. Copyright © 2019. Created by Joshua Eckblad, Academic Researcher at TiSEM in The Netherlands. 2 TABLE OF CONTENTS LEAD AUTHORS 03 Forewords Joshua G. Eckblad 06 All Investors In External Startups [email protected] 21 Corporate VC Investors https://www.corporateventuringresearch.org/ 38 Accelerator Investors CentER PhD Candidate, Department of Management 43 2018 Global Startup Fundraising Survey (Our Results) Tilburg School of Economics and Management (TiSEM) Tilburg University, The Netherlands 56 2019 Global Startup Fundraising Survey (Please Distribute) Dr. Tobias Gutmann [email protected] https://www.corporateventuringresearch.org/ LEGAL DISCLAIMER Post-Doctoral Researcher Dr. Ing. h.c. F. Porsche AG Chair of Strategic Management and Digital Entrepreneurship The information contained herein is for the prospects of specific companies. While HHL Leipzig Graduate School of Management, Germany general guidance on matters of interest, and every attempt has been made to ensure that intended for the personal use of the reader the information contained in this report has only. The analyses and conclusions are been obtained and arranged with due care, Christian Lindener based on publicly available information, Wayra is not responsible for any Pitchbook, CBInsights and information inaccuracies, errors or omissions contained [email protected] provided in the course of recent surveys in or relating to, this information. No Managing Director with a sample of startups and corporate information herein may be replicated Wayra Germany firms. without prior consent by Wayra. Wayra Germany GmbH (“Wayra”) accepts no Wayra Germany GmbH liability for any actions taken as response Kaufingerstraße 15 hereto.
    [Show full text]
  • Private Equity & Venture Capital
    VOLUME 14, ISSUE 6 ■ AUGUST 2018 PRIVATE EQUITY & VENTURE CAPITAL SPOTLIGHT THE RISE OF VENTURE AND IN THIS ISSUE GROWTH CAPITAL IN EUROPE €11bn in capital has already been secured by venture and growth capital funds focused on Europe that have closed this FEATURE 3 year; this is the highest figure seen at this stage in recent The Rise of Venture years. We put activity in the region under the microscope, examining the economic factors that have contributed to and Growth Capital in this. Europe Find out more on page 3 INDUSTRY NEWS 7 THE FACTS ■ Private Equity in the 9 PRIVATE EQUITY IN THE NORDIC Nordic Region REGION ■ Public Pension Funds 12 Investing in Private With the capital raised by managers based in the Nordic Equity region reaching record highs, we take a look at the growing private equity market in terms of fundraising activity, investor make-up and largest exits in the region. CONFERENCES 14 Find out more on page 9 RECENTLY RELEASED: THE 2018 PREQIN PRIVATE CAPITAL FUND TERMS THE 2018 PRIVATE CAPITAL All data in this newsletter ADVISOR can be downloaded to PREQIN FUND TERMS ADVISOR Excel for free Order Your Copy Download Sample Pages Sign up to Spotlight, our free monthly newsletter, providing insights into performance, investors, deals and fundraising, powered by Preqin data: Alt Credit Intelligence European and US Fund Services Awards: Best Data and Information Provider | Africa Global Funds Awards 2016: Best Research and Data Provider | The Queen’s SIGN UP Award for Enterprise: International Trade | HedgeWeek Global Awards:
    [Show full text]
  • Q1 09 Fundraising Update
    www.preqin.com Preqin Ltd. Q1 2009 Private Equity Fundraising Update Special Report 23rd April 2009 © 2009 Preqin Ltd. / www.preqin.com 2 ◄ Q1 2009 Fundraising Update Q1 Overview The Coming Turn in Fundraising As everyone is painfully aware, Fig. 1: fundraising conditions in Q1 2009 were dire. Looking across all private Final Close vs. Original Target equity fund types (venture, buyout, mezzanine, distressed, fund of funds etc.), a total of only 78 funds worldwide achieved fi nal closes, raising $49 billion between them. This represents a return to the kind of levels we were experiencing in 2004 following the trough of the previous fundraising depression. As bad as these headline statistics are, they actually disguise just how bad fundraising conditions had become. Faced with a very diffi cult market, many managers who were on the road decided to cut their losses and declare fi nal closes for funds that may have two-thirds of all funds closed were equity fundraising is set to rebound actually raised most of their funding achieving between 80% and 120% strongly: in interim closes six or twelve months of their targeted amount. Around previously – hence much of the money 15% of funds fell short by more than • LP Intentions: Preqin regularly in the ‘fi nal closes’ total was actually 20%, while 20-25% of funds exceeded surveys LP intentions, and even raised in previous quarters. Very little their targets by 20% or more. The in the depths of the credit crisis new money was committed in Q1 situation deteriorated markedly in Q4 in December 2008 these LPs 2009.
    [Show full text]
  • Entrepreneurship in Spain
    All you need to know about entrepreneurship in Spain June 2021 edition A way to make Europe EUROPEAN REGIONAL DEVELOPMENT1 FUND CONTENT Part I – STARTING POINT • Creating a startup Part II – RESOURCES FOR STARTUPS • Resources for startups • Incubators • Accelerators • Specific services suppliers Part III – FINANCING FOR STARTUPS • How to obtain financing • Private sector • Public sector • European calls • National calls Part IV – EVENTS FOR STARTUPS • Events Part V – AUTONOMOUS REGIONS • Programs and subsidies for startups This guide is intended as a collection of resources for startups in their different stages of seeking public and/or private funding 2 Part I Starting point CREATING A STARTUP IN SPAIN The steps to establish a startup are the same as for any other company. The very first one is to determine the most appropriate legal form, a decision that will be influenced by the startup´s later needs regarding participation deals and receipt of third-party investment. The most used legal forms are: Spain • Limited Liability Company (Sociedad Limitada, S.L.) in • Corporation (Sociedad Anónima, S.A.). startup Both forms can also be set up as a sole-shareholder entity (Sociedad Anónima Unipersonal, S.A.U. and Sociedad Limitada Unipersonal, S.L.U. respectively) a at the time of incorporation or be converted into a sole-shareholder entity afterwards. While there are alternatives to these legal forms, they aren´t advisable for startups that will be seeking to add partners to the project and/or third-party investors. For information purposes, these include: Freelancer (Autónomo), Private partnership (Sociedad Civil) or Jointly-Owned Entity (Comunidad de creating Bienes), or a Cooperative (Cooperativa).
    [Show full text]
  • Representative Legal Matters
    Representative Legal Matters Xinxing Chen Prior to joining Baker McKenzie, Xinxing handled the following matters: Private Equity Advised Warburg Pincus on: o a number of co-investment deals with its existing limited partners and/or new investors regarding various Warburg Pincus portfolios in China and other Asia Pacific areas, including with respect to Warburg Pincus' investment in the USD 8.7 billion take-private of 58.com (NYSE: WUBA), China's largest online classifieds marketplace. o its subscription for USD 230 million convertible note issued by Uxin (NASDAQ: UXIN), a Chinese used car trading platform. Advised Cartesian Capital Group on an investment by Tencent Holdings Ltd. in Cartesian's portfolio company, Tim Hortons China, a joint venture with the Canada-based restaurant chain. Advised DCP Capital, a leading Greater China-focused private equity firm co-founded by ex-KKR professionals, on its proposed USD 200 million investment in a Chinese leading non-alcoholic beverages manufacturer. Advised KKR on: o its investment in Joulon, an integrated platform based in Dubai providing asset management services to the oil and gas industry globally, and a series of add-on acquisitions made by Joulon in its expansion. o its investment in Mandala Energy, a South East Asia focused oil and gas exploration and production company based in Singapore. Advised Bain Capital on: o its acquisition of Xiamen Qinhuai Technology Company Limited (ChinData), a leading operator of hyperscale data centers in China, from Wangsu Science & Technology Co. Ltd., as well as on the combination of ChinData with Bain Capital's existing Bridge Data Centres platform.
    [Show full text]
  • Article Communicate
    article communicate French Chapter of the Venture Capital Handbook for 2011 PLC www.morganlewis.com Venture Capital: France Resource type: Articles: know-how Status: Law stated as at 01-Nov-2010 Jurisdiction: France A Q&A guide to venture capital law in France. The Q&A gives a high level overview of the venture capital market; tax incentives; fund structures; fund formation and regulation; investor protection; founder and employee incentivisation and exits. For a full list of recommended venture capital law firms and lawyers in France, please visit PLC Which lawyer? This Q&A is part of the PLC multi-jurisdictional guide to venture capital. For a full list of jurisdictional Q&As visit www.practicallaw.com/vchandbook. Ann Baker, Anne Tolila, Karen Noël, Olivier Edwards and Olivier Couraud, Morgan Lewis & Bockius Contents Market Tax incentives Fund structure Fund formation and regulation Investor protection Founder and employee incentivisation Exits Contributor details Anne Tolila Karen Noël Ann G Baker Olivier Edwards Market 1. Please describe briefly the venture capital market in your jurisdiction, in particular: How it is distinguished from private equity. The sources from which early stage companies obtain funding. The types of companies that attract venture capital investment. Market trends (for example, levels of investment, the type of companies invested in and where those companies are located). Venture capital and private equity Venture capital distinguishes itself by the: Early stage of development of the companies which are funded. The absence of leverage and consequently of debt in the investment, which is generally made in equity. The following figures and more can be found on www.chaussonfinance.com.
    [Show full text]
  • SL Capital Barometer 2016.Q2
    Q2 2016 Preliminary Data Private Equity BAROMETER Figures based on preliminary quarterly data from Q2 2016 Europe’s specialist private equity information provider. 1 Q2 2016 Preliminary Data Key Findings Overall European private equity ➤ The number of European private-equity-backed deals declined by 8% in the second quarter of 2016, from 381 transactions in Q1 to 350. ➤ Combined deal value improved in the second quarter, rising by 66%. ➤ The average deal value in the second quarter (€86.1m) was 81% higher than that of the first quarter (€47.6m). ➤ Overall, the year to Q2 2016 witnessed a shift towards larger deals; total deal value increased by 2%, while total volume slipped by 17%. As a result, average deal value increased by 23%. Buyouts ➤ The aggregate value of buyouts in the year to Q2 2016 (€107.4bn), was down a nominal 0.2% on the previous 12 months, while the number of deals (560) represented a 4% decline. ➤ Deal numbers increased to 148 in the second quarter, a rise of 15 from the 133 deals completed in the first quarter, and registered the highest total seen over the last six quarters. ➤ Aggregated value increased markedly, rising by 80% from the previous quarter’s total of €15.2bn, to €27.3bn. ➤ An abundance of dealflow in the small-cap (sub-€100m) and large-cap (€1bn+) ranges was responsible for the increase in the total number of buyouts in the second quarter. ➤ The small-cap range improved relative to the first quarter, increasing from 88 to 97 transactions; value rose by 25% from €3.3bn to €4.2bn.
    [Show full text]
  • Full-Time MBA Program Class of 2015 Full-Time Employment Class of 2016 Internship Employment
    Employment Data Full-Time MBA Program Class of 2015 Full-Time Employment Class of 2016 Internship Employment som.yale.edu/employmentdata Class of 2015 Full-Time Employment Status Received Job Offer Demographic Data Three Months Post Graduation (at matriculation in fall 2013) 93.4% 228 of 244 students seeking employment Mean Age 28 Gender Accepted Job Offer Three Months Post Graduation Female 39% 92.2% Male 61% 225 of 244 students seeking employment U.S. Minority 23% Class Size 278 Underrepresented Minority 10% Students Seeking Employment 244 87.8% Country of Origin Students Not Seeking Employment 31 11.2% United States 68% Starting Own Business 15 5.4% International 32% Company Sponsored 11 4.0% Average GMAT 714 Continuing Education 3 1.1% Average GPA 3.57 Postponing Search/Other 2 0.7% No Response to Survey 3 1.1% Full-Time Salary Data Overall Salary Data Base Salary1 Other Guaranteed Compensation2 25th Median 75th 25th Median 75th Percentile Percentile Percentile Percentile $105,000 $120,000 $130,000 $25,000 $34,616 $51,750 Salary by Function Base Salary1 Other Guaranteed Compensation2 Percent 25th Median 75th 25th Median 75th of Hires3 Percentile Percentile Percentile Percentile Consulting Services 37.1% $112,750 $135,000 $140,000 $25,000 $30,000 $39,000 External Consulting 28.6% $122,500 $135,000 $140,000 $25,000 $30,000 $39,250 Internal Consulting/Strategy 8.5% $85,000 $110,000 $122,500 $7,000 $27,475 $37,875 Finance/Accounting 30.4% $105,000 $122,344 $125,000 $28,000 $50,000 $60,000 Marketing/Sales 13.4% $100,000 $112,000 $117,000
    [Show full text]
  • Healthcap IV Established with Committed Capital of MSEK 3 000
    Odlander Fredrikson Group 2002-09-17 PRESS RELEASE HealthCap IV established with committed capital of MSEK 3 000 HealthCap IV was established in the summer of 2002 and now announces its final closing with a committed capital of SEK 3 000 000 000. HealthCap IV is a multi-stage venture capital fund investing in the medical sector. HealthCap invests internationally, with a focus on the Nordic region and Western Europe. The fund invests in commercialisation of medical science and innovations, in newly started companies as well as in more established enterprises. The three previous HealthCap funds will continue to make follow-on investments in existing portfolio companies. More than fifty initial investments have been made by these three funds, of which some 20 in start-up companies. Currently twelve of these companies have publicly quoted shares. HealthCap is seeking active partnership with portfolio companies and founders, providing assistance with inter alia company formation, formulation of strategies, management and financing. Investors in HealthCap IV include the 4th Swedish National Pension Fund, AGF Private Equity, AIG Global Investments, Allianz Private Equity, ATP Private Equity, Barclays Bank UK Retirement Fund, CDP Sofinov, Grove Street Advisors for CalPERS, HarbourVest Partners, MN Services, Swiss Re, Tapiola, TIFF, The Kresge Foundation, Toronto University, Vanderbilt University and Washington University. The Odlander Fredrikson Group is the exclusive investment advisor to the fund. MVision Private Equity Advisers Limited acted as global financial advisors to the Odlander Fredrikson Group, with CSFB and Handelsbanken as regional placing agents, in connection with the placing of the fund. For more information please contact Odlander Fredrikson Group Odlander, Fredrikson & Co AB Odlander Fredrikson SA Björn Odlander Peder Fredrikson tel.
    [Show full text]